Cardio-oncology & otherRandomised controlled trial
Primary Cardioprotective Effect of Sacubitril/Valsartan in Breast Cancer Patients Receiving Adjuvant Therapy
- Randomised controlled trial
- 1:4 randomisation
- prospective
Authors' conclusion
Low-dose sacubitril/valsartan may prevent CTRCD in treatment-naïve patients with early breast cancer undergoing adjuvant therapy within the first year.
Study context
- Population
- Newly diagnosed treatment-naïve patients with early breast cancer receiving adjuvant therapy (50.4 ± 8.5 years, 98% women)95 completed
- Participants
- One hundred participants
- Comparison
- Sacubitril/valsartan vs standard care
- Sacubitril/valsartann = 20
- Standard caren = 80reference
- Primary endpoint
- CTRCD (relative ≥15% decline in GLS or LVEF reduction by ≥10 percentage points to below 50%)
- Follow-up
- 12 months
Primary result
As reported in the abstract
CTRCD
Sacubitril/valsartan
0
events
Standard care
26.3%
21 of 80
P = 0.006
Original publication
Primary Cardioprotective Effect of Sacubitril/Valsartan in Breast Cancer Patients Receiving Adjuvant Therapy. Eur J Heart Fail. Published 10 July 2025. doi:10.1002/ejhf.3758
Summarised from the published abstract; every number is checked against it